

## Specialised medication benefit

The Society has introduced a Specialised Medication Benefit from 1 January 2016 for a defined list of high-cost specialised medicines. The benefit will provide members with access to specific high-cost medicines up to the limit of R125 000 per beneficiary per annum and is in addition to the routine chronic medication benefit. Beneficiaries must meet the clinical entry requirements and obtain pre-authorisation to gain access to this benefit.

The list of medicines to be funded from this benefit and the corresponding conditions are provided in the table below.

Drug	Disease
Revellex	Ankylosing spondylitis Psoriatic arthritis Rheumatoid arthritis Crohn's disease Ulcerative colitis
MabThera	Rheumatoid arthritis
Enbrel	Ankylosing spondylitis Psoriatic arthritis Rheumatoid arthritis
Actemra	Rheumatoid arthritis Juvenile idiopathic arthritis
Humira	Ankylosing spondylitis Psoriatic arthritis Rheumatoid arthritis Crohn's disease Juvenile idiopathic arthritis
Tysabri	Multiple sclerosis
Pradaxa	Artrial fibrillation
Victoza	Diabetes Type 2
Sensipar	Chronic renal disease
Forteo	Osteoporosis
TOBI	Cystic fibrosis
Pegasys	Hepatitis C
PegIntron	Hepatitis C
Ozurdex	Retinal vein occlusion

In the event of the anticipated annual cost for the medication exceeding the benefit limit, the beneficiary may submit an ex-gratia application for consideration of additional funding. Please note that the additional ex gratia benefit is not guaranteed. In the event of a PMB condition, the cost of the specialised medication will accrue to, but is not limited to the R125 000 limit.